Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multi-center, Dose Escalation, and Expansion Study of BR101801 in Adult Patients With Advanced Hematologic Malignancies

NCT04018248 is registered in ClinicalTrials.gov with Boryung Pharmaceutical Co., Ltd as lead sponsor.

NCT NCT04018248
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04018248 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multi-center, Dose Escalation, and Expansion Study of BR101801 in Adult Patients With Advanced Hematologic Malignancies
Lead sponsor
Boryung Pharmaceutical Co., Ltd
Phase
Phase 1
Overall status
Completed
Start date
April 21, 2020
Completion date
September 21, 2023
Enrollment
26 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

b cell lymphoma, chronic lymphocytic leukemia, diffuse large b cell lymphoma, follicular lymphoma, marginal zone lymphoma, peripheral t cell lymphoma, small lymphocytic leukemia, waldenstrom macroglobulinemia